Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $364
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $359 to $364.

November 08, 2023 | 9:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Vertex Pharmaceuticals and raises the price target from $359 to $364.
The news is directly related to Vertex Pharmaceuticals as Morgan Stanley maintains an Equal-Weight rating on the company and raises the price target. This could potentially lead to an increase in the stock price in the short term as it indicates a positive outlook from the analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100